Supriya targets Rs 1,600-cr revenue

Mumbai: Supriya Lifescience, which is into expansion mode, is eyeing up to Rs 1,600 crore revenue from its Lote MIDC in Ratnagiri and Ambernath facilities in the next three years, a top company executive has said. "We had a revenue of Rs 706 crore in 2024-25, and we are expecting a 20 per cent growth in FY26. With all the expansions lined up, we are expecting a surge in revenue growth. In the next 3 years, we are expecting to reach around Rs 1,600 crore revenue from our existing (Lote Maharashtra Industrial Development Corporation) and the Ambernath facility, which is expected to add to the revenue from January-Feb 2026," Supriya Lifescience MD Saloni Wagh said.